Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesWhat happens to the patients with muscle-invasive bladder cancer who refuse cystectomy after neoadjuvant chemotherapy
Indian Journal of Urology, 06/29/09
Maheshwari R et al. - Study highlights the fact that patients with muscle-invasive bladder cancer refusing cystectomy after chemotherapy are at high risk for disease-related mortality. At the same time, pts with small, clinically confined single tumors, which can be visibly and microscopically completely resected before neoadjuvant chemotherapy, are most likely to survive without cystectomy.
Methods- A prospective study to determine the outcome of pts who refuse cystectomy after receiving neoadjuvant chemotherapy
- 63 such pts evaluated between 1995-2001
- Tumor and treatment features for a median f/u of 86 mo was assessed, all pts being followed-up for >5 yrs
- 40 pts (64%) survived, with 54% of them having an intact functioning bladder
- The number and size of invasive tumors were strongly associated with overall survival
- The most significant treatment variable predicting better survival was complete resection of the invasive tumor on restaging transurethral resection (TUR) before starting chemotherapy
- Of 23 pts (36%) who subsequently died of disease, 19 (30%) relapsed with invasive cancer in bladder
- Over 90% of the surviving pts had solitary, small and low-stage invasive tumors completely resected; 83% survived w/o relapses in the bladder
Related Articles
Neoadjuvant chemotherapy with a combination of docetaxel, cisplatin, fluorouracil, and leucovorin in nonresectable advanced gastric cancer: a short communication
Medical Oncology, 11/10/09
Relevance Score: 67%
Systematic Review of Randomized and Nonrandomized Trials of the Clinical Response and Outcomes of Neoadjuvant Systemic Chemotherapy for Resectable Colorectal Liver Metastases
Annals of Surgical Oncology, 10/28/09
Relevance Score: 67%
Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer
The American Journal of Surgery, 10/08/09
Relevance Score: 67%
Neoadjuvant endocrine treatment in primary breast cancer – Review of literature
The Breast, 10/28/09
Relevance Score: 66%
Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status
Anti-Cancer Drugs, 10/16/09
Relevance Score: 66%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
A Phase I Study of Pegylated Liposomal Doxorubicin and Irinotecan in Patients with Solid Tumors
Chemotherapy, 12/11/09
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial
The Lancet - Early Online Publication, 12/11/09
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin
Cancer Chemotherapy and Pharmacology, 12/11/09
Sponsor
Article Search
Sponsor
Sponsor